0

The Agreement, among other things, consists of the Joint Entity providing 100% funding for the clinical development, manufacturing and commercial registration of the Vaccine for China and paying Generex licensing and royalty fees as follows: 1. Licensing Fee: $5,000,000 upfront fee due upon the execution of the Agreement; and then upon a successfully approved Vaccine, and an additional $20,000,000 from the net profits from the Joint Entity. 2. Royalty Fee: Once the Vaccine comes on to market for the first commercial sale, then the Joint Entity shall:

Project cost

$ 130,135

Project cost

$ 1,127,000

Project cost

$ 1,530,000

Options exercised

1,750,000

Subsequent Events (Details Narrative) - USD ($)				1 Months Ended				3 Months Ended
Subsequent Events (Details Narrative) - USD ($)	Dec. 07, 2020	Nov. 13, 2020	Nov. 09, 2020	Nov. 25, 2020	Nov. 19, 2020	Nov. 18, 2020	Nov. 17, 2020	Oct. 31, 2020
Options exercised								0
Subsequent Event [Member]
Agreement description		The Agreement, among other things, consists of the Joint Entity providing 100% funding for the clinical development, manufacturing and commercial registration of the Vaccine for China and paying Generex licensing and royalty fees as follows: 1. Licensing Fee: $5,000,000 upfront fee due upon the execution of the Agreement; and then upon a successfully approved Vaccine, and an additional $20,000,000 from the net profits from the Joint Entity. 2. Royalty Fee: Once the Vaccine comes on to market for the first commercial sale, then the Joint Entity shall:
Contracted amount					$ 273,000		$ 82,780
Project cost				$ 130,135
Subsequent Event [Member] \| Minimum [Member]
Project cost	$ 1,127,000
Subsequent Event [Member] \| Maximum [Member]
Project cost	$ 1,530,000
Subsequent Event [Member] \| Oasis [Member]
Options exercised			1,750,000			1,750,000
Proceeds from options exercised			$ 306,939			$ 306,939